131 related articles for article (PubMed ID: 33347815)
1. PARP inhibitors-understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia.
Tinker AV
Lancet Haematol; 2021 Feb; 8(2):e97-e99. PubMed ID: 33347815
[No Abstract] [Full Text] [Related]
2. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Morice PM; Leary A; Dolladille C; Chrétien B; Poulain L; González-Martín A; Moore K; O'Reilly EM; Ray-Coquard I; Alexandre J
Lancet Haematol; 2021 Feb; 8(2):e122-e134. PubMed ID: 33347814
[TBL] [Abstract][Full Text] [Related]
3. Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series.
Oliveira JL; Greipp PT; Rangan A; Jatoi A; Nguyen PL
Blood Cancer J; 2022 Jan; 12(1):11. PubMed ID: 35078980
[No Abstract] [Full Text] [Related]
4. Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy.
Matsuo K; Klar M; Mohrbacher AF; Roman LD; Wright JD
Eur J Cancer; 2021 Nov; 157():59-62. PubMed ID: 34487985
[No Abstract] [Full Text] [Related]
5. Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database.
Ma Z; Sun XM; Lu WC; Zhao ZX; Xu ZM; Lyu JY; Zhao P; Liu LH
ESMO Open; 2021 Feb; 6(1):100033. PubMed ID: 33444891
[No Abstract] [Full Text] [Related]
6. Leukaemia: Breaking tradition with PARP inhibition.
Shipman L
Nat Rev Cancer; 2016 Jan; 16(1):3. PubMed ID: 26667851
[No Abstract] [Full Text] [Related]
7. PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.
Kontandreopoulou CN; Diamantopoulos PT; Tiblalexi D; Giannakopoulou N; Viniou NA
Blood Adv; 2021 Nov; 5(22):4794-4805. PubMed ID: 34529761
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors: a treatment option for AML?
Wang L; Hamard PJ; Nimer SD
Nat Med; 2015 Dec; 21(12):1393-4. PubMed ID: 26646494
[No Abstract] [Full Text] [Related]
9. A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer.
Chiusolo P; Marchetti C; Rossi M; Minnella G; Salutari V; Distefano M; Giammarco S; Metafuni E; Minucci A; Frioni F; Gasbarrino C; Colangelo M; Orteschi D; Fagotti A; Lorusso D; Pagano L; De Stefano V; Scambia G; Sica S
Am J Hematol; 2022 Nov; 97(11):E400-E403. PubMed ID: 36054600
[No Abstract] [Full Text] [Related]
10. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
Wang L; Cai W; Zhang W; Chen X; Dong W; Tang D; Zhang Y; Ji C; Zhang M
Oncotarget; 2015 Sep; 6(29):27490-504. PubMed ID: 26314963
[TBL] [Abstract][Full Text] [Related]
12. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
[TBL] [Abstract][Full Text] [Related]
13. [Acute myelogenous leukemia and myelodysplastic syndrome after treatment with cytostatic agents].
Abrahamsen AF
Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2542-5. PubMed ID: 11070993
[TBL] [Abstract][Full Text] [Related]
14. Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy-a role for early monitoring and intervention.
Nuttall Musson E; Miller RE; Mansour MR; Lockley M; Ledermann JA; Payne EM
Leukemia; 2024 Jan; 38(1):215-218. PubMed ID: 37978317
[No Abstract] [Full Text] [Related]
15. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic relapse of de novo acute myeloid leukaemia with trilineage myelodysplasia.
Ng JP; Pati A; Strevens MJ; Swart S
Br J Haematol; 1988 Aug; 69(4):578. PubMed ID: 3165675
[No Abstract] [Full Text] [Related]
17. Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.
Faraoni I; Giansanti M; Voso MT; Lo-Coco F; Graziani G
Biochem Pharmacol; 2019 Sep; 167():133-148. PubMed ID: 31028744
[TBL] [Abstract][Full Text] [Related]
18. Very-low-dose cytarabine for myelodysplastic syndromes and acute myeloid leukaemia in the elderly.
Worsley A; Mufti GJ; Copplestone JA; Oscier DG; Hamblin TJ
Lancet; 1986 Apr; 1(8487):966. PubMed ID: 2871254
[No Abstract] [Full Text] [Related]
19. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
Yanada M; Huang X; Garcia-Manero G; O'brien S; Ravandi F; Borthakur G; Faderl S; Issa JP; Kantarjian H; Estey E
Br J Haematol; 2007 Aug; 138(4):555-7. PubMed ID: 17593249
[No Abstract] [Full Text] [Related]
20. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
García-Delgado R; de Miguel D; Bailén A; González JR; Bargay J; Falantes JF; Andreu R; Ramos F; Tormo M; Brunet S; Figueredo A; Casaño J; Medina A; Badiella L; Jurado AF; Sanz G
Leuk Res; 2014 Jul; 38(7):744-50. PubMed ID: 24795069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
